Annual EBITDA:
-$106.88M+$24.91M(+18.90%)Summary
- As of today, TARS annual EBITDA is -$106.88 million, with the most recent change of +$24.91 million (+18.90%) on December 31, 2024.
- During the last 3 years, TARS annual EBITDA has fallen by -$93.42 million (-694.07%).
- TARS annual EBITDA is now -7823.05% below its all-time high of -$1.35 million, reached on December 31, 2018.
Performance
TARS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$14.13M+$7.60M(+34.98%)Summary
- As of today, TARS quarterly EBITDA is -$14.13 million, with the most recent change of +$7.60 million (+34.98%) on September 30, 2025.
- Over the past year, TARS quarterly EBITDA has increased by +$10.73 million (+43.17%).
- TARS quarterly EBITDA is now -230.57% below its all-time high of $10.82 million, reached on March 31, 2021.
Performance
TARS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$85.67M+$10.73M(+11.13%)Summary
- As of today, TARS TTM EBITDA is -$85.67 million, with the most recent change of +$10.73 million (+11.13%) on September 30, 2025.
- Over the past year, TARS TTM EBITDA has increased by +$53.77 million (+38.56%).
- TARS TTM EBITDA is now -13875.37% below its all-time high of -$613.00 thousand, reached on September 30, 2019.
Performance
TARS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TARS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +18.9% | +43.2% | +38.6% |
| 3Y3 Years | -694.1% | +37.7% | -39.5% |
| 5Y5 Years | -2408.4% | -40.4% | -605.0% |
TARS EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -694.1% | +18.9% | at high | +68.0% | -39.5% | +44.8% |
| 5Y | 5-Year | -2408.4% | +18.9% | -230.6% | +68.0% | -2615.3% | +44.8% |
| All-Time | All-Time | -7823.1% | +18.9% | -230.6% | +68.0% | >-9999.0% | +44.8% |
TARS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$14.13M(+35.0%) | -$85.67M(+11.1%) |
| Jun 2025 | - | -$21.73M(+15.8%) | -$96.40M(+10.5%) |
| Mar 2025 | - | -$25.82M(-7.6%) | -$107.73M(+9.7%) |
| Dec 2024 | -$106.88M(+18.9%) | -$23.99M(+3.5%) | -$119.33M(+14.4%) |
| Sep 2024 | - | -$24.86M(+24.8%) | -$139.44M(+10.1%) |
| Jun 2024 | - | -$33.06M(+11.6%) | -$155.15M(-0.4%) |
| Mar 2024 | - | -$37.41M(+15.2%) | -$154.59M(-9.0%) |
| Dec 2023 | -$131.79M(-120.7%) | -$44.10M(-8.7%) | -$141.87M(-26.0%) |
| Sep 2023 | - | -$40.57M(-24.8%) | -$112.61M(-18.9%) |
| Jun 2023 | - | -$32.51M(-31.6%) | -$94.74M(-40.9%) |
| Mar 2023 | - | -$24.70M(-66.4%) | -$67.25M(-8.6%) |
| Dec 2022 | -$59.70M | -$14.84M(+34.6%) | -$61.92M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$22.70M(-352.2%) | -$61.40M(-13.2%) |
| Jun 2022 | - | -$5.02M(+74.1%) | -$54.23M(-29.9%) |
| Mar 2022 | - | -$19.37M(-35.3%) | -$41.76M(-260.8%) |
| Dec 2021 | -$13.46M(+50.0%) | -$14.32M(+7.8%) | -$11.57M(-34.2%) |
| Sep 2021 | - | -$15.53M(-308.4%) | -$8.63M(-173.4%) |
| Jun 2021 | - | $7.45M(-31.1%) | -$3.15M(+70.3%) |
| Mar 2021 | - | $10.82M(+195.2%) | -$10.61M(+54.9%) |
| Dec 2020 | -$26.90M(-531.4%) | -$11.37M(-13.0%) | -$23.52M(-93.5%) |
| Sep 2020 | - | -$10.06M(-381.2%) | -$12.15M(-349.4%) |
| Mar 2020 | - | -$2.09M(-241.1%) | -$2.70M(-341.1%) |
| Dec 2019 | -$4.26M(-215.9%) | - | - |
| Sep 2019 | - | -$613.00K | -$613.00K |
| Dec 2018 | -$1.35M | - | - |
FAQ
- What is Tarsus Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Tarsus Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of TARS is -$106.88M
What is the all-time high annual EBITDA for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high annual EBITDA is -$1.35M
What is Tarsus Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, TARS annual EBITDA has changed by +$24.91M (+18.90%)
What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of TARS is -$14.13M
What is the all-time high quarterly EBITDA for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high quarterly EBITDA is $10.82M
What is Tarsus Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, TARS quarterly EBITDA has changed by +$10.73M (+43.17%)
What is Tarsus Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of TARS is -$85.67M
What is the all-time high TTM EBITDA for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high TTM EBITDA is -$613.00K
What is Tarsus Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, TARS TTM EBITDA has changed by +$53.77M (+38.56%)